Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ,4 ]
Shao, Xiying [1 ,4 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, 1,Banshandong Rd, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4/6; inhibitor; prognostic parameters;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2-advanced breast cancer
    Hao, Chunfang
    Bai, Xuedong
    Zhang, Jie
    Meng, Wenjing
    Tong, Zhongsheng
    THORACIC CANCER, 2023, 14 (01) : 68 - 72
  • [22] Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2-Advanced Breast Cancer?
    Malorni, Luca
    Biganzoli, Laura
    BREAST CARE, 2017, 12 (05) : 288 - 289
  • [23] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [24] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [25] Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer
    Fasching, Peter A.
    Delea, Thomas E.
    Lu, Yen-Shen
    De Boer, Richard
    Hurvitz, Sara A.
    Moynahan, Aaron
    Chandiwana, David
    Lanoue, Brad
    Hu, Huilin
    Thuerigen, Astrid
    O'Shaughnessy, Joyce
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8179 - 8189
  • [26] First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN
    Martinez-Janez, N.
    Ezquerra, M. Bellet
    Sanchez, L. M. Manso
    Carrasco, F. Henao
    Torres, A. Anton
    Morales, S.
    Ortega, P. Tolosa
    Gil, V. L. Obadia
    Sampedro, T.
    Conejero, R. Andres
    Calvo-Martinez, L.
    Galve-Calvo, E.
    Lopez, R.
    de la Pena, F. Ayala
    Lopez-Tarruella, S.
    de Araguiz, B. A. Hernando Fernandez
    Ruiz, L. Boronat
    Cardenas, T. Martos
    Chacon, J. I.
    Anton, F. Moreno
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (01) : 57 - 65
  • [27] A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations
    Ma, Jing
    Li, Xuelu
    Zhang, Qianran
    Li, Ning
    Sun, Siwen
    Zhao, Shanshan
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [28] Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2-advanced breast cancer-A Chinese healthcare system perspective
    Zhu, Wentao
    Zheng, Miaomiao
    Xia, Panpan
    Hong, Wanglong
    Ma, Guoqiang
    Shen, Aizong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [30] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
12345